Miltiades Stephanou
15 Papers
29 Citations
Miltiades Stephanou is an academic researcher. The author has contributed to research in topics: Breast cancer & Breast-conserving surgery. The author has an hindex of 4, co-authored 9 publications.
Chat about Author
Papers
Targeted Intraoperative Radiotherapy Tumour Bed Boost During Breast Conserving Surgery after Neoadjuvant Chemotherapy in HER2 Positive and Triple Negative Breast Cancer.
Hans-Christian Kolberg,Gyoergy Loevey,Leyla Akpolat-Basci,Miltiades Stephanou,Peter A. Fasching,Michael Untch,Max Bulsara,Jayant S. Vaidya,Cornelia Liedtke +8 more
TL;DR: Although survival estimates trended towards favouring TARGIT-IORT, no significant differences could be observed and the significantly positive result for OS favoring TAR GIT IORT in the whole cohort of 116 patients could not be reproduced in this subset analysis of patients with TN and HER2 positive tumours.
Neoadjuvant Chemotherapy with Docetaxel, Carboplatin and Weekly Trastuzumab Is Active in HER2-Positive Early Breast Cancer: Results after a Median Follow-Up of over 4 Years.
Hans-Christian Kolberg,Leyla Akpolat-Basci,Miltiades Stephanou,Bahriye Aktas,Carla Hannig,Cornelia Liedtke +5 more
TL;DR: The anthracycline-free regimen TCH is effective and safe in the neoadjuvant therapy of HER2-positive breast cancer, yielding DFS, DDFS and OS probabilities comparable to the results of adjuvant trials.
Targeted Intraoperative Radiotherapy Tumour Bed Boost during Breast-Conserving Surgery after Neoadjuvant Chemotherapy - a Subgroup Analysis of Hormone Receptor-Positive HER2-Negative Breast Cancer.
Hans-Christian Kolberg,György Lövey,Leyla Akpolat-Basci,Miltiades Stephanou,Peter A. Fasching,Michael Untch,Oliver Hoffmann,Max Bulsara,Jayant S. Vaidya,Cornelia Liedtke +9 more
TL;DR: The improved overall survival demonstrated previously could be reproduced in the HR-positive HER2-negative subgroup and these data give further support to the inclusion of such patients in the TARGIT-B (Boost) randomised trial that is testing whether IORT boost is superior to EBRT boost.
Intraoperative radiotherapy as a boost after neoadjuvant chemotherapy: DFS after a median follow-up of 4 years.
TL;DR: The boost irradiation as an intraoperative procedure showed a further decrease of local recurrence rates down to 1,75% and this approach was adapted to patients after neoadjuvant chemotherapy (NACT).
5
Breast Conserving Surgery in Combination With Targeted Intraoperative Radiotherapy Compared to Mastectomy for In-breast-tumor-recurrence
Hans-Christian Kolberg,H. Niesing,Jayant S. Vaidya,Leyla Akpolat-Basci,A. Maguz,Oliver Hoffmann,Gyoergy Loevey,Miltiades Stephanou,Cornelia Kolberg-Liedtke +8 more
TL;DR: In this article , a comparative analysis of overall survival and quality of life (QoL) was performed for patients with in-breast-recurrence and either mastectomy or BCS and TARGIT-IORT.
4